Abstract: The invention involves an exposed aggregate architectural coating to be applied to existing concrete structures. The invention includes a method of preparing and roughening an existing concrete structure surface, mixing the components of the exposed aggregate architectural coating, applying the coating to the existing concrete structure, spreading the coating to a thickness of one-fourth of an inch or thinner, using a trowel, gauge rake, or other method to smoothen the coating, allowing the coating to cure, applying a surface retarder once the exposed aggregate architectural coating has stiffened, allowing the surface retarder to cure for twenty-four hours, and washing the surface with a pressure-washer to remove the surface retarder, then “acid-washing” the surface to remove residue and create a desired texture. The resulting applied exposed aggregate architectural coating will have an exposed aggregate finish that is durable and suitable for high vehicular and pedestrian traffic areas.

Abstract: An optical element includes an optical surface including a ceramic material. The optical element further includes a coating that includes a bifunctional molecule arranged on the optical surface. The bifunctional molecule includes a first functional group and a second functional group. The first functional group forms a covalent bond to the ceramic material of the optical surface, and the second functional group includes an aromatic functional group. The optical element further includes a carbon-containing material non-covalently bonded to the second functional group of the bifunctional molecule of the coating.

Abstract: A fertilizer composite comprising a simple or complex granular solid fertilizer and a coating covering the fertilizer granules, the coating comprising from 10-90 wt % of a first wax component comprising linear alpha olefin wax having a carbon number in the range of from 20 to 100 and a congealing point in the range of from 40 to 80° C.

Abstract: The application relates to a process for the production of alpha-springene (formula (I)) and beta-springene (formula (II)) from geranyl geranyl acetate (formula (III)).

Abstract: Systems and methods are provided for upgrading of methane and/or small alkanes to distillate boiling range hydrocarbons. The upgrading is performed using a reaction system where various types of integration are provided from downstream reaction stages to upstream reaction stages. Such integration can include recycle of various reaction products as well as thermal integration. Having a reaction system that begins with reforming of hydrocarbons and finishes with production of distillate can enable unexpected synergies between downstream reaction stages and upstream reaction stages.

Abstract: A process of producing 1,3-butadiene includes: a first step of obtaining gases containing 1,3-butadiene by an oxidative dehydrogenation reaction of a raw material gas with a molecular oxygen-containing gas in the presence of a metal oxide catalyst, the raw material gas containing 1-butene and 2-butene and having a proportion of 2-butene to a sum of 1-butene and 2-butene, which is defined as 100% by volume, being not less than 50% by volume; a second step of cooling the produced gases obtained in the first step; and a third step of separating the produced gases having undergone the second step into molecular oxygen and inert gases and other gases containing 1,3-butadiene by selective absorption to an absorbing solvent, wherein the concentration of methyl vinyl ketone in the produced gases having been cooled in the second step is 0% by volume or more and not more than 0.03% by volume.

Abstract: A process is described for producing 1,3-butanediol, wherein an ester of poly-(R)-3-hydroxybutyrate such as formed by transesterification with an alcohol is reduced by hydrogenation in the presence of a skeletal copper-based catalyst to provide 1,3-butanediol. The 1,3-butanediol may be transesterified by reaction with additional poly-(R)-3-hydroxybutyrate ester to produce (R)-3-hydroxybutyl (R)-3-hydroxybutyrate.

Abstract: A method is disclosed for improving the energy efficiency of biorefinery drying operations through integration of a dryer that utilizes the heat of condensation of process vapors to dry material whose emissions are captured with energy recovery. The dryer separates clean process vapors (e.g., ethanol) and steam from vapors containing volatile organic compounds and entrained materials, to minimize the need for vapor cleanup. An indirect dryer condenses vapors in a tube dryer similar to a steam tube dryer, but utilizing compressed process vapors, transferring the heat to wet material undergoing drying. The resulting exhaust vapors are either directed to a process stage that requires heat (e.g., distillation) and minimizes the need for vapor cleanup or to an out-of-contact heat exchanger that produces vapors for process use, or to another dryer as an additional effect. Mechanical-vapor recompression or thermal-vapor recompression are employed to produce vapors that optimize overall energy recovery.

Abstract: A method for purification and separation of cannabinoids, such as cannabidiol and tetrahydrocannabinol, e.g., from dried hemp and cannabis leaves can use a continuous simulated moving bed process, a batch column chromatography method, or a single column, and a combination of one or more of a sequence of purification steps including: filtration, decolorization, activation or decarboxylation, dewaxing, polishing, and crystallization to separate a cannabinoid from the cannabis plant and to provide various cannabinoid products. The cannabinoid products can be used in various pharmaceutical and nutraceutical applications.

Abstract: The invention relates to an improved process and system for the synthesis of dimethyl ether (DME) from a feedstock comprising H2 and COx, wherein x=1-2. The process according to the invention comprises (a) subjecting the gaseous mixture comprising synthesis gas originating from step (c) to DME synthesis by contacting it with a catalyst capable of converting synthesis gas to DME to obtain a gaseous mixture comprising DME; (b) subjecting a gaseous mixture comprising the gaseous mixture originating from step (a) to a separation-enhanced reverse water gas shift reaction; and (c) subjecting the gaseous mixture originating from step (b) to DME/synthesis gas separation to obtain DME and a gaseous mixture comprising synthesis gas, which is recycled to step (a). Herein, the feedstock is introduced in step (a) or step (b) and the molar ratio of H2 to COx in the gaseous mixture which is subjected to step (b) is at least (x+0.8). Also a system for performing the reaction according to the invention is disclosed.

Abstract: Methods of synthesizing compounds comprising fluorinated aryl groups are disclosed, wherein said methods utilize hydrogen bond directed photocatalytic hydrodefluorination.

Abstract: Compositions include ether ester compounds formed from gamma-branched aliphatic alcohols, lubricating oil base stocks containing such ester compounds, and lubricating oil compositions containing such ester compounds. Methods can include making and formulating compositions containing ether ester compounds formed from gamma-branched aliphatic alcohols.

Abstract: A compound of the formula (I) wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3-C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom, and * denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes.

Abstract: Disclosed in the present invention are an emodin succinyl ester compound, a preparation method therefor and a use thereof, the emodin succinyl ester compound having the structure as represented by formula I (R being a C1-5 alkyl group). The method provided in the present invention has a simple method course, and may effectively save time in synthesis and reduce costs, being simple to operate, being easy to implement, and being suitable for industrial production. Experiments show that the emodin succinyl ester compound of the present invention may better promote the healing of diabetic wounds than emodin, and may be used for preparing a drug for promoting the healing of diabetic wounds.

Abstract: A method for converting an N,N-dialkylamide compound into an ester compound includes using a fourth period transition metal complex as a catalyst. The fourth period transition metal complex is obtained by a reaction of a precursor having a fourth period transition metal with a nitrogen-containing compound or a phosphorus-containing compound.

Abstract: A method for cycloaddition of dimethyl muconate is disclosed. According to the method, a direct transferring of a solid phase trans,trans-dimehtyl muconate into a reactor pre-filled with ethylene gas increases the efficiency of the reaction and suppress side reactions resulting an improvements in yield and purity. Furthermore, the method is capable of obtaining a high yield of dimethylcyclohex-2-en-1,4-dicarboxylate at a lower cost, and therefore is also useful for the mass synthesis of dimethyl terephthalate.

Abstract: The present invention relates novel methods of synthesizing terphenyl compounds and in particular to novel methods for the synthesis of a compound of Formula I or intermediates thereof.

Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.

Abstract: The present disclosure relates to the photoactive agent having an N—O—C?O—C band and being mixed with a liquid crystal aligning agent, a manufacturing method of photoactive agent comprising a primary solution preparation step for preparing a primary solution by mixing and dissolving cyclohexanone oxime in a solvent, a secondary solution manufacturing step for preparing a secondary solution by mixing anhydride in the primary solution, a reaction step for proceeding a synthesis reaction of the photoactive agent in a reaction solution in which a catalyst is mixed with the secondary solution, and an extraction step for extracting the photoactive agent in the reaction process.

Abstract: Crystalline polymorph forms of neurotrophic agent 2,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide (J147), and process for producing the crystalline polymorphic form are provided.

Abstract: In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of terpenoid cores. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising a terpenoid core or scaffold, such as 6/7/5 tricycloalkanes. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to tunably and scalably assemble common terpenoid cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: A method for manufacturing a higher purity nitrile solvent by purifying a nitrile solvent containing an impurity, e.g an imine. The nitrile solvent may contain an imine and a conjugated diene, a carbonyl compound, or a high-boiling material as impurities. A method for purifying a nitrile solvent, such as isobutyronitrile, including bringing nitrile solvent containing an imine, e.g., as an impurity, into contact with an acidic aqueous solution having a pH of 3 or less, such as hydrochloric acid; bringing the nitrile solvent having been contacted with acidic aqueous solution into contact with an aqueous sodium hydrogen sulfite solution; bringing the nitrile solvent having been contacted with the aqueous sodium hydrogen sulfite solution into contact with an alkaline aqueous solution, such as an aqueous sodium hydroxide solution; and distilling the nitrile solvent having been contacted with the alkaline aqueous solution.

Abstract: Provided are compounds of formula (I), or a stereoisomer, mixture of stereoisomers, deuterated analog, tautomer, solvate or pharmaceutically acceptable salt thereof, compositions, method of making and uses thereof.

Abstract: Process P1 for the manufacture of a secondary fatty alcohol, said process P1 comprising synthesizing an internal ketone K1 by a process P0 comprising the decarboxylative ketonization reaction of a fatty acid or the like in a liquid phase with a metal compound as catalyst in a reaction medium, wherein a ketone K2 at liquid state, which is identical or similar to the internal ketone K1, is introduced into the reaction medium, and subjecting the internal ketone K1 to a hydrogenation reaction with hydrogen gas as hydrogenating agent to form the secondary fatty alcohol. Use of the secondary fatty alcohol manufactured by the process P1 for the manufacture of an internal olefin or of an internal olefin sulfonate.

Abstract: The present disclosure is directed to provide a process capable of producing a sulfonic acid group-containing monomer in a good yield, which can be used as a raw material of fluorine-based polymer electrolytes, such as membranes for fuel cells, catalyst binder polymers for fuel cells, and membranes for chlor-alkali electrolysis. A process for producing a sulfonic acid group-containing monomer represented by the general formula (3) includes the step of mixing and stirring a cyclic compound represented by the general formula (1) and a silanol compound represented by the general formula (2).

Abstract: An alkyl sulfate ester containing a carbonyl group or a salt thereof. The compound is represented by the following formula: R1—C(?O)—(CR22)n—(OR3)p(CR42)q-L-OSO3X wherein R1, R2, R3, R4, L, X, n, p and q are as defined herein. Also disclosed is a production method for making the alkyl sulfate ester.

Abstract: A salt, in particular a lithium salt, that is usable in alkali metal cells and/or batteries, and/or electrolytes and/or additives for same is described. To achieve good ion conductivity as well as temperature and high voltage stability and to prevent corrosion of aluminum, for example a current collector, the salt includes at least one alkali metal ion and/or at least one ammonium compound and at least one anion that contains at least one unfluorinated (N,N-dialkylamide)sulfonyl group and/or at least one unfluorinated (N,N-dialkylamide)sulfoximide group, and at least one (perfluoroalkyl)sulfonyl group. An electrolyte, an additive, a cell, a battery, and a preparation method, are also described.

Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid.

Abstract: A highly effective synthetic route to produce donor-acceptor azetines through the highly enantioselective [3+1]-cycloaddition of silyl-protected enoldiazoacetates with aza-ylides using chiral copper(I) catalysis is provided. In one embodiment, the 2-azetidine cycloaddition products undergo generation of 3-azetidinones by reactions with nucleophiles that produce a broad spectrum of peptide products by the retro-Claisen reaction provided by facile strain with high efficacy and complete retention of enantiopurity. This ring opening reaction uncovers a new methodology for the attachment of chiral peptide units to a variety of amines and alcohols, and tolerates a broad scope of nucleophiles including naturally occurring amines, alcohols, amino acids, and other nitrogen based nucleophiles.

Abstract: A method of synthesising a compound of formula (I): (I) from a compound of formula (II): (II) where R8 is either: (i) ProtO3; or (ii) a group of formula (A1) in formula (I) and (A2) in formula (II): (A1), (A2).

Abstract: Disclosed are an endocyclic thiamidinoamide-arylamide compound and a pharmaceutical composition comprising the compound described above, and the use of the compound or pharmaceutical composition in the treatment of hepatitis B. In particular, disclosed is a compound that can be used as an HBV replication inhibitor and has the structure as shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Abstract: A method of selectively inhibiting pathogenic microbes includes: providing a compound that is functional as a selective antimicrobial having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a pathogenic microbe with the compound such that the pathogenic microbe is selectively inhibited; wherein: ring A is a cycloalkyl, heterocycloalkyl, aryl, heteroaryl, or polycycle combination thereof; X is S, SO, or SO2; Y is a linker or bond; Z is CH, CR2, or N; Z1 is C or N to form an imidazopyridine; each Z2, Z3, or Z4 is independently CH, CR2, or N; each Z5 or Z6 is C or CH; each R1, R2, R3 and/or R4 is independently a substituent; m is 0, 1, 2, 3, or 4; and n is zero or a positive integer.

Abstract: A compound can have a structure of Formula A, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof: wherein ring A is a phenyl, indolyl, naphthyl, or benzothiazolyl; X is S, SO, or SO2; Y is a linker or bond; Z is CH, CR2, or N; Z1 is C or N to form an imidazopyridine; each Z2, Z3, or Z4 is independently CH, CR2, or N; each Z5 or Z6 is C or CH; each R1, R2, and R3 is independently a substituent, and at least one of R1, R2, or R3 is a substituent other than a hydrogen; m is 0, 1, 2, 3, or 4; and n is 0 or a positive integer. The compounds can have specific substituent patterns.

Abstract: Provided are novel compounds of Formulas (I) and (II), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful as dual FKBP12/FKABP inhibitors. Also provided are pharmaceutical compositions comprising the novel compounds of Formulas (I) and (II) and their use in treating Parkinson's disease.

Abstract: 3,5-Diarylidenyl-N-substituted-piperid-4-one analogs, and pharmaceutically acceptable derivatives thereof, are useful in the treatment or prevention of disorders including cancer, autoimmune disorders, inflammatory disorders, and fibrotic disorders. The compounds are included in pharmaceutical compositions, and are useful for treating disorders, such as cancer associated with aberrant Stat3 pathway activity. The compositions further include another therapeutic agent, such as an anticancer drug. Such compounds or compositions thereof are used to treat resistant and/or metastatic cancers. Methods also inhibit Stat3 pathway activity in a cell. Other methods are useful for making the pharmaceutical compounds. Synthetic methods are also useful for making the compounds. The compounds and compositions are useful as a fluorescent probe.

Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: Compounds of Formula I are provided: R1 is —OR5, m is an integer from 0 to 5, n is an integer from 0 to 2, each R2 is independently selected from hydrogen, halogen, and alkyl, R3 is selected from hydrogen, alkyl, cycloalkyl, aryl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkyloxyalkyl, aralkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkylaminoalkyl, and heterocycloalkyl, R5 is an alkyl, each R4 is independently hydrogen or alkyl, and each of R2, R3, R4, and R5 is independently optionally substituted. Compounds of Formula I are included in pharmaceutical compositions for the treatment of a subject exposed to a botulinum toxin.

Abstract: Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods of treatment and/or prophylaxis of proliferative diseases, including cancer, and more specifically, pancreatic cancer.

Abstract: The present application provides a novel phenyl derivative, 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof, which is useful for regulating mitochondria activity, reducing adiposity, treating diseases including diabetes and diabetes-associated complications.

Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

Abstract: Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.

Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.

Abstract: Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R1, R2, R3 and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.

Abstract: There is provided herein a compound of formula (I) wherein R1, R2, n, X, Q, L, m, R3 and p are as defined herein, which compounds are useful in the treatment of treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

Abstract: Abnormally long r(CUG)n repeat expansion is believed to be the major cause of Myotonic dystrophy type 1 (DM1) because it binds to muscleblind-like 1 (MBNL 1) protein which regulates RNA splicing, leading to the mis-splicing of more than 100 pre-mRNAs. The rational design of oligomers with alternating bisamidine and melamine structure resulted in good binding affinity to the RNA target because of a multivalent effect. The oligomers also showed excellent activity in disrupting nuclear foci, reversing the mis-splicing of IR minigene, and sabotaging the toxic RNA biosynthesis. Excellent activity in Drosophila based DM1 models was also observed for the oligomers, rescuing the climbing ability of the flies upon oral treatment.

Abstract: The present invention relates to macrocyclic compounds which are capable of selective binding to a target saccharide (e.g. glucose), making them particularly well suited for use in saccharide sensing applications. The present invention also relates to processes for the preparation of said compounds, to compositions and devices comprising them, and to their use in the detection of a target saccharide.

Abstract: Fragrance precursor compounds of the formula (I) may be derived from hydrazides and fragrance aldehydes and ketones. The fragrance precursor compounds may be used in composition having washing or cleaning agents, cosmetic agents and air care agents. A method for long-lasting fragrancing of surfaces using the fragrance precursor compounds and agents is also disclosed.

Abstract: The present invention relates to a new path to synthesize crystalline Tafamidis polymorphs starting from a Tafamidis acetic acid adduct. In addition, this invention relates to a process to synthesize Tafamidis (2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid*(2R,3R,4R,5S)-6-(methyl-amino)-hexane-1,2,3,4,5-pentol), new Tafamidis crystalline polymorphs, a pharmaceutical compositions comprising the new crystalline polymorphs and to the therapeutic use of such new polymorphs.

Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.